After the discovery of the BRCA1 and BRCA2 genes in the 1990s, the first guidelines for the care of high-risk individuals with hereditary breast and ovarian cancer stated that “there was insufficient evidence to recommend for or against prophylactic surgery” [44,45]. This evidence concerns the gene BRCA2 and ovarian cancer.